Wedbush Reaffirms “Outperform” Rating for Travere Therapeutics (NASDAQ:TVTX)
Wedbush reissued their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. A number of other analysts also recently commented on TVTX. Guggenheim reiterated a “buy” rating and set a $47.00 target […]
Wedbush reissued their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. A number of other analysts also recently commented on TVTX. Guggenheim reiterated a “buy” rating and set a $47.00 target […]
